Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma

Inclusion Criteria

• •Histologic Documentation: Core needle biopsy or surgical specimen that confirms intrahepatic cholangiocarcinoma (ICC). Patients must be determined to be unresectable by a multidisciplinary team that includes a hepatobiliary surgeon.
• •No prior liver radiation therapy or immunotherapy for cholangiocarcinoma.
• •Only one previous single agent chemotherapy for ICC allowed.
• •Patient may have prior liver resection.
• •Age \> 18 years of age.
• •Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (see Appendix E)
• •Child's Pugh score of A (see Appendix F)
• •Life expectancy of greater than 4 months
• •Normal organ and marrow function as outlined in the protocol.
• •Willingness to use effective contraceptive methods during the study. Patient may participate in the female (or female partner of male subject), either is not of childbearing potential (defined as postmenopausal for \> 1 year or surgically sterile) or is practicing two forms of contraception. Sexually active male participants must agree to use a physical barrier method (male latex rubber condom with or without spermicide).
• •Pre-certification for the 90Y TARE should be performed prior to enrollment on this study.
• •All patients must be informed of the investigational nature of this study and must have the ability to understand and the willingness to sign a written informed consent document.